Concurrent XXXX and @entity1150 in a @entity1 with ANCA-associated vasculitis: case report and review of literature.

@entity1 @entity1667 @entity548 @entity1333 @entity786 @entity1150 @entity1211
Antineutrophil cytoplasmic antibody-associated @entity1333 (AAV) is an uncommon but potentially life threatening disease in @entity1 . @entity548 ( @entity548 ) is a well recognized but lethal complication. The incidence of @entity1211 ( @entity1211 ) is higher in @entity1 with AAV, especially in those with active disease. However, the simultaneous occurrence of both @entity548 and @entity1211 has rarely been reported.Herein, we describe a 14-year-old female with AAV who developed concomitant @entity1150 ( @entity1150 ) and @entity548 within 3  days after hospitalization. She was successfully treated with timely plasmapheresis and @entity1667 pulse therapy. @entity1211 did not occur during discontinuation of anticoagulant. On reviewing the English literature, 5 AAV @entity1 with coexisting @entity1211 and @entity548 have been reported. When faced with @entity548 , whether or not to keep anti-coagulation treatment is a dilemma. Some of the @entity1 kept receiving anti-coagulation treatment, whereas others undergoing inferior vena cava filter implantation. Glucocorticoids and @entity786 or other immunosuppressant agents were prescribed in all @entity1 . All of the cases survived after treatment for concurrent @entity1211 and @entity548 , and received short- or long-term anticoagulation treatment after discharge.To the best of our knowledge, this is the first report of a pediatric @entity1 with AAV presenting with coexistent @entity1211 and @entity548 . @entity1211 should be considered to be a sign of disease flare-up, and early plasmapheresis with immunosuppressant therapy can rescue this fatal complication.
